Description: Ensysce Biosciences, San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.
Home Page: www.ensysce.com
ENSC Technical Analysis
7946 Ivanhoe Avenue
La Jolla,
CA
92037
United States
Phone:
858 263 4196
Officers
| Name | Title |
|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | Pres, CEO & Director |
| Mr. David C. Humphrey CPA | CFO, Sec. & Treasurer |
| Mr. Geoffrey Birkett | Chief Commercial Officer |
| Dr. Jeffrey Millard Ph.d. | Chief Operating Officer |
| Mr. Richard Wright M.B.A., MSE | Chief Bus. Officer |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board & Chief Medical Officer |
| Dr. Linda Pestano Ph.D. | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.0161 |
| Price-to-Sales TTM: | 1.947 |
| IPO Date: | 2018-02-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |